Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Blair William & Co. IL

Blair William & Co. IL grew its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.2% during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,282 shares of the biopharmaceutical company’s stock after purchasing an additional 27 shares during the quarter. Blair William & Co. IL’s holdings in Regeneron Pharmaceuticals were worth $813,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Pinney & Scofield Inc. acquired a new stake in Regeneron Pharmaceuticals during the fourth quarter worth about $25,000. E Fund Management Hong Kong Co. Ltd. raised its stake in Regeneron Pharmaceuticals by 344.4% during the first quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 31 shares during the period. Tompkins Financial Corp acquired a new stake in Regeneron Pharmaceuticals during the first quarter worth about $32,000. Curat Global LLC acquired a new stake in Regeneron Pharmaceuticals during the first quarter worth about $32,000. Finally, American National Bank & Trust acquired a new stake in Regeneron Pharmaceuticals during the first quarter worth about $44,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on REGN shares. Guggenheim increased their price objective on shares of Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the stock a “buy” rating in a research note on Friday, August 1st. Morgan Stanley restated an “overweight” rating and issued a $761.00 target price (up previously from $754.00) on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Royal Bank Of Canada upped their target price on shares of Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the stock a “sector perform” rating in a research report on Monday, August 4th. Robert W. Baird decreased their target price on shares of Regeneron Pharmaceuticals from $759.00 to $652.00 and set a “neutral” rating for the company in a research report on Friday, April 25th. Finally, Bank of America decreased their target price on shares of Regeneron Pharmaceuticals from $575.00 to $547.00 and set an “underperform” rating for the company in a research report on Thursday, April 17th. One research analyst has rated the stock with a sell rating, seven have given a hold rating, sixteen have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $841.30.

Regeneron Pharmaceuticals Trading Up 0.6%

Shares of NASDAQ:REGN opened at $563.00 on Monday. The stock has a market capitalization of $59.67 billion, a price-to-earnings ratio of 14.19, a PEG ratio of 1.91 and a beta of 0.33. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60. The company has a 50 day moving average price of $536.80 and a 200 day moving average price of $598.52.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, topping analysts’ consensus estimates of $8.43 by $4.46. The firm had revenue of $3,675,600 billion during the quarter, compared to analysts’ expectations of $3.30 billion. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The firm’s revenue for the quarter was up 3.6% compared to the same quarter last year. During the same period last year, the firm posted $11.56 earnings per share. On average, research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Monday, August 18th will be issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date is Monday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 8.87%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.